Prostate Cancer

November 23rd 2023

Patients with prostate cancer who received 18 months of androgen deprivation therapy were more likely to recover their serum testosterone levels and to recover quicker than those who received 36 months of therapy.

November 17th 2023

The FDA has expanded the indication for enzalutamide to include patients with high-risk nonmetastatic castration-sensitive prostate cancer.

November 6th 2023

The median overall survival with niraparib, abiraterone acetate, and prednisone was 30.4 months vs 28.6 months with abiraterone acetate and prednisone alone.

October 26th 2023

The median radiologic progression-free survival was 12.02 months in the 177Lu-PSMA-617 group vs 5.59 months in the androgen receptor pathway inhibitor change group.